B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) Vertex Pharmaceuticals Inc stake
total: 185
Tweedy, Browne Co All Funds (US) VRTX trades
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 3
- Reduced:
- 8
- Held since:
- 2023 Q3
- Held for:
- 12 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Tweedy, Browne Co All Funds (US) holds 40,121 Vertex Pharmaceuticals Inc (VRTX) shares with a market value of roughly $19.93M accounting for 1.51% of the overall portfolio. To date, the estimated cost basis is nearly $350.44 for "buy" trades and estimated average "sell" price is $433.16. Tweedy, Browne Co All Funds (US) first purchased VRTX in 2023 Q3, initially acquiring 75,004 shares. Since the initial investment in Vertex Pharmaceuticals Inc (VRTX), Tweedy, Browne Co All Funds (US) has made 11 more transactions.
When did Tweedy, Browne Co All Funds (US) buy Vertex Pharmaceuticals Inc (VRTX)?
Tweedy, Browne Co All Funds (US) first invested in Vertex Pharmaceuticals Inc (VRTX) in 2023 Q3 at the reported quarter-end price of $347.74 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s VRTX stake?
The estimated cost basis for Vertex Pharmaceuticals Inc (VRTX) stake is around $350.44 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $350.44
- Weighted AVG sell price:
- $433.16
Tweedy, Browne Co All Funds (US)'s historical trades in Vertex Pharmaceuticals Inc
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.51%
|
40,121
|
$496.73
|
$19,929,304
|
-0.66% (-266)
|
-0.01%
|
|
2026 Q1
|
1.43%
|
40,387
|
$446.54
|
$18,034,411
|
+3.16% (+1,239)
|
+0.04%
|
|
2025 Q4
|
1.43%
|
39,148
|
$453.36
|
$17,748,137
|
+0.21% (+83)
|
+0%
|
|
2025 Q3
|
1.33%
|
39,065
|
$391.64
|
$15,299,417
|
+4.86% (+1,812)
|
+0.06%
|
|
2025 Q2
|
1.54%
|
37,253
|
$445.20
|
$16,585,036
|
-2.77% (-1,063)
|
-0.04%
|
|
2025 Q1
|
1.65%
|
38,316
|
$484.82
|
$18,576,363
|
-5.70% (-2,315)
|
-0.08%
|
|
2024 Q4
|
1.10%
|
40,631
|
$402.70
|
$16,362,104
|
-24.20% (-12,969)
|
-0.25%
|
|
2024 Q3
|
1.19%
|
53,600
|
$465.08
|
$24,928,288
|
-1.37% (-746)
|
-0.02%
|
|
2024 Q2
|
1.17%
|
54,346
|
$468.72
|
$25,473,057
|
-18.52% (-12,353)
|
-0.27%
|
|
2024 Q1
|
1.31%
|
66,699
|
$418.01
|
$27,880,849
|
-0.10% (-65)
|
-0%
|
|
2023 Q4
|
1.33%
|
$406.89
|
-10.99% (-8,240)
|
|||
|
2023 Q3
|
1.40%
|
$347.74
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.